270 related articles for article (PubMed ID: 15486518)
1. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.
Nimatoudis I; Zissis NP; Kogeorgos J; Theodoropoulou S; Vidalis A; Kaprinis G
Int Clin Psychopharmacol; 2004 Nov; 19(6):331-6. PubMed ID: 15486518
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR; DuPont RL; Hedges D; Haskins JT
J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
[TBL] [Abstract][Full Text] [Related]
4. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
6. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
Meoni P; Salinas E; Brault Y; Hackett D
J Clin Psychiatry; 2001 Nov; 62(11):888-93. PubMed ID: 11775049
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
Rudolph RL; Feiger AD
J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
Thase ME
J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
[TBL] [Abstract][Full Text] [Related]
9. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
10. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder.
Hackett D; Haudiquet V; Salinas E
Eur Psychiatry; 2003 Jun; 18(4):182-7. PubMed ID: 12814852
[TBL] [Abstract][Full Text] [Related]
11. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
Rickels K; Etemad B; Khalid-Khan S; Lohoff FW; Rynn MA; Gallop RJ
Arch Gen Psychiatry; 2010 Dec; 67(12):1274-81. PubMed ID: 21135327
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials.
Katz IR; Reynolds CF; Alexopoulos GS; Hackett D
J Am Geriatr Soc; 2002 Jan; 50(1):18-25. PubMed ID: 12028242
[TBL] [Abstract][Full Text] [Related]
14. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
Feighner JP; Entsuah AR; McPherson MK
J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
Montgomery SA; Tobias K; Zornberg GL; Kasper S; Pande AC
J Clin Psychiatry; 2006 May; 67(5):771-82. PubMed ID: 16841627
[TBL] [Abstract][Full Text] [Related]
17. Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.
Lydiard RB; Pitrosky B; Hackett D; White C
J Clin Psychiatry; 2004 Jun; 65(6):838-44. PubMed ID: 15291662
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial.
Kasper S; Herman B; Nivoli G; Van Ameringen M; Petralia A; Mandel FS; Baldinetti F; Bandelow B
Int Clin Psychopharmacol; 2009 Mar; 24(2):87-96. PubMed ID: 21456104
[TBL] [Abstract][Full Text] [Related]
19. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
Cunningham LA
Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
Montgomery SA; Locklear JC; Svedsäter H; Eriksson H
Int Clin Psychopharmacol; 2014 Sep; 29(5):252-62. PubMed ID: 24394383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
